Question Bank › Management is buying the same thing twice

Management is buying the same thing twice

Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r

Calls Tested
987
Answered YES
16
Hit Rate
1.6%
rare by design

Myomo, Inc. (MYO) — this company's answers

NO on the Q3 2018 call 2018-11-05 C
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO based on transcript. Need determine if management describes current middle of copying proven business into additional places with demand visible. Let's analyze. Company Myomo: sells MyoPro orthosis for upper limb paralysis. They are scaling up commercialization. They opened new sales regions by hiring business development managers and clinical support staff. These professionals recruited and trained O&P clinics to provide MyoPro. Then local digital marketing campaigns and patient screening days. In quarter added six new O&P providers, total 13 locations in metro areas including Atlanta, Sacramento, Seattle. Continue expand distribution footprints. Screening days from 12 Q1 to 25 Q2 to 100 Q3. Reimbursement pipeline 222 units. Adding around 40 new patients per month. Sold 94 units in all 2017. Also expanding to adolescents, children's hospitals, AFM. Testing prototypes pediatric device. International expansion: signed O&P provider in Denmark, conducted screening days in UK, began calling potential distributors. Question: Does management describe company as CURRENTLY IN MIDDLE OF COPYING A PART OF ITS OWN BUSINESS THAT IS ALREADY WORKING INTO ADDITIONAL PLACES WHERE SAME DEMAND IS ALREADY VISIBLE? Need identify proven instance: U.S. sales and marketing model? They have proven sales regions? They are replicating by hiring BDM and clinical support, recruiting O&P clinics, running screening days. They have record 130 new patients entering reimbursement process. Pipeline 222 units. They are adding new O&P providers in metro areas. Demand visible? They have screening days with patient prospects. They are adding locations where demand already visible? They mention "local digital marketing campaigns and hosted patient screening days to evaluate patients" - so demand is generated. But is demand already identified at destination? They are expanding to new regions with O&P providers. They have "new own key providers" certified. They are aiming at demand they can see? They have screening days with patients. But is it "demand already visible" like waitlists or unserved orders? They have pipeline of 222 units representing potential revenue. But that's overall, not necessarily at new locations. They are adding new O&P providers in metro areas. They likely have patient prospects from marketing.

← Back to the full MYO analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe the company as CURRENTLY IN THE MIDDLE OF COPYING A PART OF ITS OWN BUSINESS THAT IS ALREADY WORKING INTO ADDITIONAL PLACES WHERE THE SAME DEMAND IS ALREADY VISIBLE — that is, does management convey that a specific, identifiable piece of the company has been proven out in real operation, and that the company is right now standing up further instances of that same piece in other locations, customers, markets, channels, applications, or lines, where management can already point to demand or commitment waiting for those new instances? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation in which all three of the following come through as a present-tense reality: (1) A PROVEN INSTANCE THAT ALREADY WORKS. Management points to something concrete inside the company that has demonstrably performed in real operation — actual customers, orders, volumes, output, utilization, throughput, or economics already produced by it in the recent period. It may take whatever form fits the industry: a facility, site, plant, line, store, clinic, branch, route, or region; a product, service, program, or offering; a customer type, application, vertical, or channel; a method of producing, selling, or delivering. What matters is that management treats this instance as settled — it works, and management can say what it has produced — rather than as something still being tested or awaiting proof. (2) COPIES ARE PHYSICALLY BEING STOOD UP NOW. Management describes additional instances of that same thing actually being built, opened, hired for, converted, launched, qualified, or brought up at this moment — construction underway, sites secured and in fit-out, people already hired for the next locations, the second and third instances in commissioning, the offering being extended into named additional markets or customer sets. The replication must be in motion, not merely announced, budgeted, contemplated, or contingent on money, permits, or partners the company does not have. (3) DEMAND IS ALREADY IDENTIFIED AT THE DESTINATION. Management conveys that the new instances are being aimed at demand it can already see rather than demand it hopes to create — for example counterparties already asking for them, work or customers already committed or waiting in those places, waitlists or unserved orders the existing instance cannot absorb, or management explaining that the proven instance is turning away or unable to serve business that the new ones will take. Management should also convey, directly or plainly in substance, that this replication is large relative to the company as it stands today and that the reported results reflect mostly the original instance — so the numbers describe the company before the copies exist. The essence is ONE phenomenon: an operator that has stopped asking whether the thing works and is now in the physical act of multiplying it against demand already in view. The industry, the unit being replicated, and the form of the build may vary widely. Answer NO if the company is growing inside its existing footprint, with no additional instances of a proven unit being stood up. NO if the thing being replicated has not yet been proven in real operation — a pilot without results, a launch with nothing sold, a first site not yet open. NO if the additional instances are only planned, authorized, under study, or dependent on financing, approvals, or decisions not yet obtained. NO if the replication is routine and ordinary for this company — the usual annual cadence of openings, line extensions, or account additions that management does not present as changing the company's level of business. NO if the new instances are being aimed at demand management merely believes exists, described through market size, pipeline, or opportunity rather than demand already visible at the destination. NO if the replication is chiefly defensive — replacing a failing unit, relocating, consolidating, or offsetting decline elsewhere. NO if the multiplication is already substantially complete and reflected in current results. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
PUMP ProPetro Holding Corp. Q4 2023 2024-02-21 C+
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
SYY Sysco Corporation Q1 2023 2022-11-01 C+
VSEC VSE Corporation Q3 2022 2022-10-28 B+
FSLR First Solar, Inc. Q3 2022 2022-10-28 C+
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
GDS GDS Holdings Limited Q2 2021 2021-08-17 C+
TPIC TPI Composites, Inc. Q3 2018 2018-11-11 C
ALB Albemarle Corporation Q3 2018 2018-11-08 B
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
FOLD Amicus Therapeutics, Inc. Q1 2018 2018-05-08 C+
AOSL Alpha and Omega Semiconductor Limited Q2 2018 2018-02-07 B
VSAT Viasat, Inc. Q4 2017 2017-05-23 C+
PLAB Photronics, Inc. Q2 2017 2017-05-17 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.

More from the question bank

Told to get biggerAnalysts converge on an emerging driverThe new engine is already turningTempo shift: the rhythm of the business has Paying a named price today to serve businessPriced like the old business, running like aAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.